Cargando…
Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker
Cholangiocarcinoma (CCA) is a devastating disease due to resistance to traditional chemotherapies and radiotherapies. New therapeutic strategies against CCA are urgently needed. This study investigated the role of lipocalin-2 (LCN2) in human cholangiocarcinoma as a potential therapeutic target and d...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080596/ https://www.ncbi.nlm.nih.gov/pubmed/27782193 http://dx.doi.org/10.1038/srep36138 |
_version_ | 1782462751676825600 |
---|---|
author | Chiang, Kun-Chun Yeh, Ta-Sen Wu, Ren-Chin Pang, Jong-Hwei S. Cheng, Chi-Tung Wang, Shang-Yu Juang, Horng-Heng Yeh, Chun-Nan |
author_facet | Chiang, Kun-Chun Yeh, Ta-Sen Wu, Ren-Chin Pang, Jong-Hwei S. Cheng, Chi-Tung Wang, Shang-Yu Juang, Horng-Heng Yeh, Chun-Nan |
author_sort | Chiang, Kun-Chun |
collection | PubMed |
description | Cholangiocarcinoma (CCA) is a devastating disease due to resistance to traditional chemotherapies and radiotherapies. New therapeutic strategies against CCA are urgently needed. This study investigated the role of lipocalin-2 (LCN2) in human cholangiocarcinoma as a potential therapeutic target and diagnostic marker. So far, the role of LCN2 in cancer is still controversial and studies regarding the role of LCN2 in CCA are limited. LCN2 knockdown inhibited CCA cell growth in vitro and in vivo through induction of cell cycle arrest at G0/G1 phases and decreased metastatic potential due to repression of epithelial-mesenchymal transition (EMT). Overexpression of LCN2 in CCA cells increased cell metastatic potential. We showed for the first time that the N-myc downstream regulated gene 1 (NDRG1) and NDRG2, known as tumor suppressor genes, are negatively regulated by LCN2 in CCA cells. LCN2 concentration in bile was higher in patients with CCA than that in patients with gallstones, with a cutoff value of 20.08 ng/ml making this a potential diagnostic marker. Higher LCN2 expression was associated with worse survival in patients with CCA. LCN2 is a promising target for CCA treatment and bile LCN2 level is a potential diagnostic marker for CCA. |
format | Online Article Text |
id | pubmed-5080596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50805962016-10-31 Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker Chiang, Kun-Chun Yeh, Ta-Sen Wu, Ren-Chin Pang, Jong-Hwei S. Cheng, Chi-Tung Wang, Shang-Yu Juang, Horng-Heng Yeh, Chun-Nan Sci Rep Article Cholangiocarcinoma (CCA) is a devastating disease due to resistance to traditional chemotherapies and radiotherapies. New therapeutic strategies against CCA are urgently needed. This study investigated the role of lipocalin-2 (LCN2) in human cholangiocarcinoma as a potential therapeutic target and diagnostic marker. So far, the role of LCN2 in cancer is still controversial and studies regarding the role of LCN2 in CCA are limited. LCN2 knockdown inhibited CCA cell growth in vitro and in vivo through induction of cell cycle arrest at G0/G1 phases and decreased metastatic potential due to repression of epithelial-mesenchymal transition (EMT). Overexpression of LCN2 in CCA cells increased cell metastatic potential. We showed for the first time that the N-myc downstream regulated gene 1 (NDRG1) and NDRG2, known as tumor suppressor genes, are negatively regulated by LCN2 in CCA cells. LCN2 concentration in bile was higher in patients with CCA than that in patients with gallstones, with a cutoff value of 20.08 ng/ml making this a potential diagnostic marker. Higher LCN2 expression was associated with worse survival in patients with CCA. LCN2 is a promising target for CCA treatment and bile LCN2 level is a potential diagnostic marker for CCA. Nature Publishing Group 2016-10-26 /pmc/articles/PMC5080596/ /pubmed/27782193 http://dx.doi.org/10.1038/srep36138 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Chiang, Kun-Chun Yeh, Ta-Sen Wu, Ren-Chin Pang, Jong-Hwei S. Cheng, Chi-Tung Wang, Shang-Yu Juang, Horng-Heng Yeh, Chun-Nan Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title_full | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title_fullStr | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title_full_unstemmed | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title_short | Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker |
title_sort | lipocalin 2 (lcn2) is a promising target for cholangiocarcinoma treatment and bile lcn2 level is a potential cholangiocarcinoma diagnostic marker |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080596/ https://www.ncbi.nlm.nih.gov/pubmed/27782193 http://dx.doi.org/10.1038/srep36138 |
work_keys_str_mv | AT chiangkunchun lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT yehtasen lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT wurenchin lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT pangjonghweis lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT chengchitung lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT wangshangyu lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT juanghorngheng lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker AT yehchunnan lipocalin2lcn2isapromisingtargetforcholangiocarcinomatreatmentandbilelcn2levelisapotentialcholangiocarcinomadiagnosticmarker |